Call for Abstract

14th International Conference on Biosimilars and Pharma Innovations, will be organized around the theme “”

World Biosimilars 2020 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in World Biosimilars 2020

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Biosimilar products are required by regulatory authorities to have appropriate and comparable quality, safety and efficacy with a reference biologic product .Analysis of biosimilars and biologics structures to be a standout amongst the most critical angle towards the biologics and biosimilar advancement process. Bio-analytical strategies for process advancement and approval and also utilization of generation innovations, for example, disposables and store network co-ordinations can enable organizations to build up office adaptability. This biosimilars worldwide occasion additionally incorporates Bio-analytical strategies, Formulation, Bioassay for equivalence and power testing, GMP protein examination, LC/MS investigation for revelation, preclinical, and clinical projects. While small changes in these parameters can impact the various chemical permutations for a given biotherapeutic, innovators can, under certain circumstances, change the host cell, fermentation process, purification process, and even manufacturing site, but the product can be validated without undertaking a complete new product development review.

  • Track 1-1Biochemical and Biosimilars Characterization
  • Track 1-2Biosimilars multimodal techniques
  • Track 1-3Biosimilars bio analytical methods
  • Track 1-4Bioassays for comparability and potency testing
  • Track 1-5LC/MS analysis for discovery, preclinical and clinical programs
  • Track 1-6Biosimilars GMP protein analysis
  • Track 1-7Biosimilars electrophoresis

Pharmaceutics is the discipline of pharmacy that deals with the process of turning a new chemical entity (NCE) or old drugs into a medication to be used safely and effectively by patients. It is also called the science of dosage form design. The largest pharma market globally is for musculoskeletal drugs. The segment accounted for 14% of the global total in 2017. Cardiovascular, oncology and ant-infective drugs are the second third and fourth largest markets.

 

  •  Drug delivery
  •  Pharmaceutical formulation
  •  Pharmaceutical manufacturing
  •  Physical pharmacy
  •  Pharmaceutical jurisprudence
  •  Dispensing pharmacy
  •  Pharmaceutical technology

 

Pharmaceutical formulation is defined as the process in which different chemical substances are combined to produce a final medicinal product which can be either solid, semisolid or liquid formulations. This session is ventured around topics like, Drug Delivery design, versatile polymer in drug delivery and Controlled Drug Delivery, Novel Drug interactions, improvement of pharmaceutical product, Sustained Drug Delivery Systems, may be a distinct architecture session that plays an important role in the fields of drug formulation and development.

A biologic medicine is defined as a medicine that contains one or more active substances made by or derived from a biological source. In the broadest sense, biological medicines include any substance made in the laboratory from a living organism. This broad definition includes vaccines, immunotherapies, biosimilars, gene therapy, and stem cell or tissue therapy. Bio medicine can also be defined as a medicine whose active substance is made by a living organism.

 In the field of biologics, the new avenue has created towards clinicians because explorations have created for better disease management. In the treatment of elements like psoriasis, rheumatic arthritis, certain cancer inflammation, bowel diseases etc. Showed some good outcomes because of using biologics. Biosimilar insulin which are newly formed are likely to enter the insulin landscape as patents for major branded insulin products ready to expire in the next few years. The emerging biosimilar like filgrastim, pegfilgrastim, recombinant blood products, therapeutic products vaccine biosimilar, anti-bodies growth hormones, biosimilar peptide, all these are used to sound knowledge on biosimilars development on drugs.

  • Rapid screening methods
  • Environmental Monitoring
  • Particulate matter

 

 

Clinical trials for biosimilars should exhibit much identical security what is a lot of, viability to the reference item, together with consecutive PK/ metallic element and viability/security trials. Controllers expect PK/PD similarity info from a phase I clinical trial trial can bolster encourage viability/ successfulness evaluations in crucial phase III clinical trial trials. Stay solitary phase III clinical trial investigations or joined section I/III outlines while not supporting PK info area unit most likely not attending to be acknowledged. Clinical similarity stipulations might fluctuate on a item-by-item premise subject to a risk primarily based approach. Three-arm phase I clinical trial trials area unit more and more getting used to point out equivalence between the biosimilars and 2 licensed diversifications of the same reference item which will exist in numerous markets, permitting developers to proceed with crucial trials employing a single version of the reference product.

  • Biosimilars clinical trials
  • Clinical PK/PD studies
  • Toxicological studies
  • Risk management and quality affairs
  • Targeted cell line development
  • Case studies and clinical models
  • Biologics product life cycle and sustainable market returns

 

The development of biologics necessitate overcoming ton several challenges. With initial steps of ideas of biologics, their issues, necessities for early clinical developments it's a great deal required that correct scientific and strategic approaches area unit taken for the winning development of follow-on-biologics. Moreover, the requirement for overcoming the challenges continues within the late clinical steps, drug safety factors and labelling needs. Conjointly it's a lot of needed currently to develop a drug product in accordance to quality intentionally (QbD).This monetary unit biosimilars conference can explore the multiple sides of current challenges in Biosimilars development. This biosimilars conference can specialise in multiple aspects of biosimilars development to with success deliver safe, potential and efficacious life product to the market.

  • Biopharmaceuticals development
  • Quality by Design for Biologics and Biosimilars
  • Implimentation of the BPCI Act
  • Advertising, promotion and labelling essentials
  • Unique considerations for biologics
  • Comparability for biologics
  • Drug safety essentials
  • Late clinical development essentials
  • Early clinical development essentials
  • Biologics in genetic disorders
  • Biopharmaceuticals development

 The drug subjected to drug development undergoes range of trials and area unit screened at totally different stages to provide a final potent drug supposed for the treatment of varied diseases. throughout this method numerous properties area unit checked to check whether or not the drug is non-toxic to living system and is therapeutic or not. victimisation appropriate excipients and technological preparations the active substances area unit developed into final indefinite quantity type. The last product is that the Actual composition of preparation, producing specification. Drug formulation will have a considerable impact on nearly each quality characteristic of Associate in Nursing API together with efficiency, bioavailability, solubility, dosage, route of administration and stability. In immune offers epithelial duct drug formulation R&D services for primary stage and diagnosing candidates with a special prominence in nanoparticle based mostly drug delivery technology.

  • Sources of Drug Formulation
  • Electrochemical Methods

 

The global biosimilars market is growing at an exponential rate. The CAGR from 2015 to 2020 is projected at over 22%. The biosimilars market is predicted to be around $6.2 billion by 2020 from only $2.3 billion in 2015. By the top of this decade the biosimilars would surely occupy 27% of the entire pharmaceutical market. Moreover, with the worldwide rise in concern for more accessible-improved- cost effective healthcare, biosimilar drugs would be a more apt choice to the payers, end users, manufacturers over the costly reference biologics. Originator biologics are as costly as about $100,000 per annum per patient. Biosimilars on the contrary are often offered at a 30-40% lower cost than that of the reference product. However, with all the success stories and opportunities there also lies a sobering 50% failure rate in developing and obtaining license towards marketing of biosimilars. The biosimilars market is categorized into mainly four zones – North America(USA and Canada); Europe(UK, Germany, Spain, Italy, France and Rest of Europe); Aisa-Pacific( China, India, Japan, South Korea) and remainder of the planet ( LATAM and MENA). Key players of the biosimilars market include Amgen, Hospira, Teva, Sandoz International GmbH, Dr. Reddy’s Laboratory, Biocon, Roche, Celltrion, Catalent, Mylan and Merck. There are also certain other companies which are gaining importance in biosimilar de velopment like LeanBio Pro-Spain, PPD-USA, SGS Life Sciences-UK, Therapeutic Proteins International-USA. The biosimilars development is especially concentrated within the therapeutic domains of oncology, blood disorders, autoimmune disorders, endocrine disorders and infectious diseases.

  • Return on Investment(ROI) for Biosimilars
  • Biosimilars Pharmacoeconomic Modelling
  • CAGR of biologics and biosimilars
  • Future of next generation biosimilars
  • SWOT Analysis of Biosimilars
  • Challenging potential & Competing Vs Generics
  • Penetration and uptake of biosimilars in different disease sectors
  • Pharmacoeconomic Modelling of Biosimilars
  • Risk management plan (RMP) for Biosimilars

 

 The safeguarding of product secret, its formulations and other process parameters by law is typically covered by IPR. It includes those as patents, copyrights, industrial design rights, trademarks etc. IPR is of prime importance within the field of biologics and biosimilars. Most scientist and industries tend to retain their monopoly business by exercising the IPR. The very name Biosimilars involves the occurrence of property rights laws and by-laws. Hence this session is of utmost interest to the attorneys and law personnel. Currently, the US provides 12 years of exclusivity for brand spanking new biological products under the Biologics price war and Innovation Act (BPCIA).The provision providing 12 years exclusivity was buried inside the 20,000-page healthcare law. Eight years of exclusivity would keep biologic medicines out of the hands of the many who need them. Prices frequently exceed $100,000.

Competitions and/or success at intervals this company business square measure determined by the winning patent strategy that principally pertains to the generic market entry. Generic and branded drug makers each the patent strategy proximally belongs to the Hatch-Waxman Act statutory theme and ANDA litigations. The Hatch-Waxman Act enacted in 1984 with modification in 2003 expedited the entry of generics at associate early stage-thereby finishing the battle of branded generic ANDA of blockbuster medication. All constant the Biologics price struggle and Innovation (BPCI) Act has maximized the branded-generic patent duel at intervals the biologics realm by imposing a litigated framework on follow-on-biologics

An bureau analysis of drug costs from 1999 to 2004 found that the discount from generic competition was simply 6 June 1944 with one generic competition, however jumps to forty eighth with 2 generic competitors, fifty six with 3, sixty one with four and sixty seven with 5 generic producers throughout a market. at intervals a pair of years of the expiration of the patent of the favored drug alkaliser in 1997, generics of alkaliser accounted ninetieth of the treatment’s total sales, and thus value the worth|the value} for patients was concerning 100% of its pre-generic price. European patents on biological treatments began to expire in 2000, and in Gregorian calendar month 2006, Sandoz and Biopartners with success received EMEA approval for the first European biogenerics, 2 products containing human somatotrophic hormone.

  • Licensing of biosimilars
  • BLA filing for biosimilars
  • Regulatory prospects of BRIC countries
  • Biowaiver approval for biosimilars

 A Biosimilars bio therapeutic item is comparative (but not identical) as so much as quality, wellbeing, Associate in Nursing viability to an effectively licensed reference item. Not within the least like nonspecific very little particles, it’s arduous to send such naturally complicated things in lightweight of convoluted grouping forms. The worldwide biosimilars advertise is developing quickly as licenses on blockbuster life medications terminate and alternative healthful services elements centre on drop-off of expenses. Biologics square measure among the foremost elevated price medicines on the worldwide market nowadays, that suggests the necessity for stripped-down effort decisions. In developing markets, biosimilars formally supply a lot of moderate prices, that square measure tempting, additionally as crucial to economies wherever expensive medications are not monetarily realizable.

  • Track 12-1Biosimilars China and Asia Pacific
  • Track 12-2Biosimilars India
  • Track 12-3Biosimilars USA
  • Track 12-4Biosimilars Europe

Biological medicines are far more structurally complex and very sensitive to manufacturing conditions and thus harder to characterize and produce than small molecule drugs. Even minor changes in manufacturing may cause significant variations of the cellular systems used for biological production, also on differences within the structure, stability, or other quality aspects of the top product, all of which have the potential to affect tolerability and or efficacy and increase the danger of immune responses. Owing to these issues, specific regulatory guidance on biosimilars is continuously evolving, and there's some disagreement on which studies got to be implemented to approve a biosimilars. According to current literature, the subsequent points on biosimilars deserve consideration: Biosimilars development is characterized by global harmonization, although several not fully answered questions remain regarding extrapolation of indications, switching or interchange ability, and tolerability; in patients with rheumatic diseases, the tolerability and efficacy of biosimilars in clinical practice remain to be established; several medical and patient associations have published position papers on biosimilars requesting that safety, efficacy, and traceability be carefully considered; long-term post marketing studies should be implemented to permit physicians to realize confidence in biosimilars.

  • Track 13-1Monoclonal antibody
  • Track 13-2Fusion protein
  • Track 13-3Biologic drug
  • Track 13-4Anti–tumor necrosis factor
  • Track 13-5Biotechnologic drug

 Biopharmaceutical information processing endeavors to use info technology, sequence-and structure-based bioinformatics analyses, molecular modelling and simulations, and applied math knowledge analyse towards biological drug development. Development of knowledge bases containing the experimental data on biophysical stability, safety along with molecular sequence.

  • Track 14-1Applications of computation in biologic drug development
  • Track 14-2Physics-based molecular modelling
  • Track 14-3Protein sequence-structural contexts and degradation reaction mechanisms
  • Track 14-4De risk biopharmaceutical development
  • Track 14-5Creation of databases and data mining
  • Track 14-6Pre-clinical immunogenicity risk assessment of biotherapeutics

With Europe that made-up because of the uptake of biosimilars over a decade agone, the results of Brexit would be doubtless tougher on UK. Presently UK isn't to any extent further guaranteed to follow the foundations of EMA. Additionally analysis grants from Innovative Medicines Initiative and Horizon 2020 would no a lot of be offered to UK. All the same, EMA has its headquarters in London, UK. The so arising complications would positively have sure consequences on the Biosimilars state of affairs in UK and EU.

  • Track 15-1Brexit- Pros and Cons to European pharma market
  • Track 15-2Post Brexit changes in biosimilars regulation in UK
  • Track 15-3Fate of biosimilars clinical trials in UK
  • Track 15-4Research funding from European organizations to UK based research laboratories

 The objective of this work was to counsel the biowaivers potential of biopharmaceutical arrangement that are noted to increase the solubility, dissolution, oral absorption of water insoluble medication. Biopharmaceutics arrangement and invitro and invivo classification discusses concerning ADME pathways of varied medication. This additionally includes BCS biowaivers, In vitro diffusion cells for dissolution testing in formulation development, In vitro presymptomatic ADME/BCS testing. Till in vitro and in vivo correlation achieves the desired degree, the biosimilars drug will not be able to meet the wants of the primary drug candidate. Hence the proportion of BCS and IVIVC based mostly biowaivers ar fairly low ~0.5-1% of total pharmaceutical product.

  • Track 16-1BCS biowaivers
  • Track 16-2Preclinical and clinical testing for oral drug delivery
  • Track 16-3Waiver for In vivo bioavailability or bioequivalence
  • Track 16-4Consideration of biowaiver extensions for BCS class III drugs
  • Track 16-5In vitro diffusion cells for dissolution testing in formulation development
  • Track 16-6Dissolution testing in drug formulation
  • Track 16-7In vitro preclinical ADME/BCS testing
  • Track 16-8In vitro drug product research.

This session of the Biosimilars 2018 can verify the long run and Food and Drug Administration initiatives that have already been proclaimed to include increased following and follow-up of post selling police investigation problems, planned enhancements in AERS, and pilots of latest post market drug-monitoring ways and ADR connected problems. Biosimilar tips for pharmacovigilance follow and pharmacoepidemiology are the points that shall be set stress throughout this session. U.S. average annual defrayal growth from 2002 to 2007 was Sixteen Personality Factor Questionnaire for biologics, compared with three.7% for medicine. In same proportion pharmacovigilance for biosimilars has been relatively quite different pharmaceutical merchandise.

 The legal problems regarding the follow-on-biologics associate degreed biosimilars are one of the foremost aspects that want an open discussion. Before the actual advent of biosimilars to the market legal problems have up in numbers in their biological process stages. Known organizations have filed cases against alternative 2 claims their rights and for other legal allegations related to the product. This track is dedicated to discussion of all such cases that has been argued among the court of law.

By 2002, the authority had approved thirty six new biologics, followed by thirty seven additional in 2003, another forty in 2004 and thirty-nine additional in 2005. By 2006, the leading class of biological treatment, the red corpuscle attention recombinant glycoprotein (EPO), generated $14 billion in sales revenues, or forty p.c quite the popular ancient pharmaceutical, Lipitor. quite three hundred therapeutic antibodies presently are in clinical development and trials, compared to solely thirteen that already are wide accessible because of legal problems.

 Pharmaceutical drug delivery technologies enhance drug absorption, efficacy, and patient expertise. style maskers increase the business viability of your pharmaceutical merchandise by neutralizing the sturdy, bitter tastes of bound oral medical formulations. Bioavailability of medicines at intervals the system square measure typically achieved by increasing the dissolution rate with specialised drug delivery sweetening merchandise. Enhancing the drug delivery technology of final pharmaceutical formulation will increase its business success. The most routes of drug delivery square measure oral, injection/infusion, and percutaneous. Drug-eluting stents and different implantable drug delivery devices square measure conferred, conjointly as outwardly applied devices. Once combined with applicable targeting moieties, drug-coated nanoparticles, drug-encapsulating liposomes and nanotubes, and tree-like dendrimers alter organ and tissue targeting.

\r\n

\r\n The use of applied science in drugs and a lot of specifically drug delivery is close to unfold apace. presently several substances square measure underneath investigation for drug delivery and a lot of specifically for cancer medical care. Curiously pharmaceutical sciences square measure mistreatment nanoparticles to reduce toxicity and aspect effects of medication and up to recently did not notice that carrier systems themselves could impose risks to the patient. the type of hazards that square measure introduced by mistreatment nanoparticles for drug delivery square measure on the far side that exhibit by standard hazards obligatory by chemicals in classical delivery matrices

 These biotechnology derived medicine were at one time administered by injection alone, but today, solutions for inhaled, percutaneous, and even oral delivery square measure obtainable or underneath investigation for several established merchandise .Super molecule delivery technologies, since unprotected or untargeted delivery of sequence therapies or RNAi is unthinkable. We have a tendency to then advance to developments in percutaneous delivery technology, which includes active systems wherever delivery is driven by micro needles or energy applied via ultrasound or lasers.

Pharmacogenomics is that the study could be a few person’s genes response to specific medication. this is {often |this can be} often the somewhat new field that mixes medication (the science of drugs) and genetics (the study of genes and their functions) to develop productive, safe medication and doses that will be tailored to a person’s genetic makeup. This session plans to bolster the novel drug administration by intermixture medication and modifying in light-weight of hereditary varieties in placid reaction.

Pharmaceutical chemistry encompasses drug design, drug synthesis, and the evaluation of drug efficacy and drug safety. Drug discovery is the core of pharmaceutical chemistry.

  • Design of safer chemicals and products
  • Process Chemistry Considerations
  • Structure-activity relationships of drug Moiety
  • Synthetic chemistry including combinatorial methods
  • Invivo and in vitro bio transformation of drugs
  • Modelling and designing of small compounds
  • Physico chemical and biological factors that contribute to drug action
  • Medicinal Radio compounds or Radiopharmaceuticals
  • Global Pharmaceutical Policy
  • Impurities and Impurity Profile Significance in API

 

Pharmaceutical companies can play a paramount role in the digital revolution of healthcare. But grabbing this opportunity requires identifying the right actions. Pharmaceutical companies are running hard to keep measure with changes brought about by digital technology. Mobile communications, the cloud, advanced analytics, and the Internet of Things are among the new innovations that are starting to transform the healthcare industry in the ways they have already transformed the media, retail, and banking industries. Pharma executives are well aware of the disturbing potential and are examining with a wide range of digital enterprise. Yet many find it hard to determine what initiatives to scale up and how, as they are still unclear what digital success will look like five years from now. This article aims to remedy that. The digital pharma market is relied upon to reach $ 11.2 billion in 2013. This market is further anticipated that would develop up to $23.5 billion in 2018 with a compound yearly development rate (CAGR) of 16.1%.

  • Pharma: just trying to start something new with the help of Digital.
  • Digital Pharma: A New Culture
  • Digital Pharma & Customer Service
  • Digital Pharma Opportunities & Challenges

1. Vaccine Drug Delivery System

Vaccine is a material that activates an immunologically mediated resistance to a disease but not necessarily an infection.  Vaccines generally consist of killed or attenuated organisms or subunits of organisms or DNA encoding antigenic proteins of pathogens. Delivery of antigens from oil-based adjuvants such as Freund's ancillary lead to a reduction in the number of doses of vaccine to be administered but due to toxicity concerns such as inductions of granulomas at the injection site, such ancillary is not widely used.  Search for safer and potent ancillary resulted in the formulations of antigen into delivery systems that administer the antigen in particulate form rather than solution form.

  • Cancer vaccines
  •   Human vaccines
  •   HIV/AIDS vaccines
  • HPV vaccines
  • Therapeutic vaccination for autoimmune diseases
  • Novel vaccines
  • Clinical trials     

2. Sustained Release Drug Delivery system

Sustained-release drug delivery dosage forms are designed to release a drug at a prearranged rate by maintaining a fixed drug level for a particular period of time with minimum side effects. It basically optimizes the biopharmaceutical, pharmacokinetic and pharmacodynamics properties of a drug in such a way that its utility is maximized, side-effects are reduced and the cure of the disease is achieved.

3. Prolonged Release Drug Delivery System

Prolonged-release drug delivery system makes a simple cylindrical device with a small release hole which is investigated by a dynamic mathematical simulation model based on the two-dimensional Fick's law of diffusion. Effects of the release hole radius, height, and radius of the device and hydrodynamic diffusion boundary layer formed on the device, the surface is numerically evaluated. It releases the active ingredients through a hole slowly so that it can release for an extended period of time.

 

It is a very advanced approach in which the drug/small molecules are nanoencapusaluted in nanocarriers (NCs). The basic idea about encapsulate drug is it allows efficient loading of drug molecules inside the NCs which in further reduces systemic toxicity associated with drugs.

Pharmaceutical manufacturing, Drug manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs by pharmaceutical companies. The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.